2-Indolone Derivatives and Use Thereof
AssigneeTianjin Zhengcheng Medical Technology Co., Ltd.
InventorYuna Lu
Life of this patent
Estimating the term…
Abstract
A 2-indolone derivative and a pharmaceutically acceptable salt thereof is provided. Also provided are a pharmaceutical composition containing a pharmaceutically acceptable carrier, and the 2-indolone derivative and the pharmaceutically acceptable salt thereof. The 2-indolone derivative and the pharmaceutically acceptable salt thereof can be used for preparing a drug for treating and preventing related diseases such as fibrosis and the like, and can also be used for preparing a drug for treating and preventing related diseases such as excessive or abnormal cell proliferation and the like.
Claims12
A compound represented by formula I or a pharmaceutically acceptable salt thereof:
- wherein:
- R1 and R2 are each independently selected from H, deuterium (D), C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, 3-6-membered saturated or unsaturated carbocyclic ring, 3-6-membered saturated or unsaturated heterocyclic ring containing nitrogen (N) and/or oxygen (O) and/or sulphur (S), wherein the C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, 3-6-membered saturated or unsaturated carbocyclic ring, 3-6-membered saturated or unsaturated heterocyclic ring containing nitrogen (N) and/or oxygen (O) and/or sulphur (S) are optionally substituted by zero or more substituents selected from deuterium, halogen, cyano, hydroxyl, sulfhydryl;
- or R1 and R2, together with the atoms to which they are attached, form a ring;
- R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29 and R30 are each independently selected from hydrogen (H) or deuterium (D);
- the conditions are R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29 and R30 are all hydrogen, the R1 or R2 group contains at least one deuterium atom.
Dependencies are inferred from the claim text.